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AbstrAct
Identification of vaccine target antigens (Ags) that induce Ag-specific Th1 
immunity is the first step toward the development of a tuberculosis vaccine. Here, 
we evaluated the Mycobacterium tuberculosis (Mtb) protein Rv3628, a soluble 
inorganic pyrophosphatase, as a vaccine target and characterized the molecular 
details of its interaction with dendritic cells (DCs). Rv3628 activated DCs, increasing 
their expression of cell surface molecules and augmenting their production of TNF-α, 
IL-1β, IL-6, and IL-12p70. Rv3628 mediated these effects by binding to TLR2 and 
activating downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. 
Rv3628-stimulated DCs induced the expansion of OVA-specific CD4+ and CD8+ T cells, 
which secreted IFN-γ and IL-2. Rv3628-specific effector/memory T cells expanded 
to a similar extent as those stimulated with ESAT-6 Ag in samples of lung and spleen 
cells collected from Mtb-infected mice. Finally, an Rv3628 subunit vaccine adjuvanted 
with dimethyldioctadecylammonium liposomes containing monophosphoryl lipid-A 
caused significant reductions in bacterial counts and lung inflammation after challenge 
with the hyper-virulent Mtb K strain. Importantly, protective efficacy was correlated 
with the generation of Rv3628-specific CD4+ T cells co-producing IFN-γ, TNF-α and 
IL-2 and exhibiting an elevated IFN-γ recall response. Thus, Rv3628 polarizes DCs 
toward a Th1 phenotype and promotes protective immunity against Mtb infection.
INtrODUctION
Tuberculosis (TB) caused by Mycobacterium 
tuberculosis (Mtb) remains a prevalent health threat 
worldwide [1-3]. The Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) vaccine, the only currently 
licensed vaccine against TB, has been in use for 
approximately a century and has helped to control the 
global TB burden; however, its protective efficacy 
gradually wanes over time, eventually leading to an 
inability to prevent pulmonary TB in adults [4]. Therefore, 
the development of more efficacious TB vaccines is a top 
priority in TB research. 
The generation of a robust Th1-type CD4+ T cell 
response is pivotal in providing anti-TB immunity. 
Generally, T cells are primed and educated in draining 
lymph nodes by dendritic cells (DCs) and consequently 
migrate to infected tissues to combat Mtb. Thus, DCs 
play key roles in programming and establishing T cell 
memory responses by translating innate immunity into 
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immunological memory [5]. In the context of vaccine 
development, the initial encounter between DCs and 
an antigen (Ag) is the first critical event that shapes the 
type and duration of an immune response [1, 2]. Thus, 
an Ag that can induce DC maturation and consequently 
induce robust cellular immunity is of great interest for the 
development of an effective TB vaccine. 
Previously, our group sought to identify suitable 
vaccine Ag targets with the aim of developing a multistage 
vaccine [6-9]. We have characterized many well-known 
and lesser-known Ags in vitro, particularly focusing 
on their interactions with DCs. While screening Ag-
DC interactions, we discovered that Rv3628 induced a 
Th1-biased immune response via DC activation. Upon 
evaluating the Ag-DC interaction, we identified Rv3628 
as a strong DC activator. 
Rv3628 is a unique soluble inorganic class I 
pyrophosphatase (PPase) that, as a metal-dependent 
enzyme that converts pyrophosphate into orthophosphate, 
is essential for maintaining cell viability [10, 11]. In 
addition, in contrast to the PPases of other bacteria, 
Rv3628 contains two non-conserved amino acid residues, 
His21 and His86, in its active site [11]. This protein has 
been suggested as a possible target for the rational design 
of anti-TB agents [12]. Rv3628 has been identified in 
culture supernatants, membranes, cytosolic fractions and 
cell wall fractions of Mtb [13-16]. Rv3628 is constitutively 
expressed and is important for the survival and growth of 
Mtb in vitro; in particular, it is an essential factor that is 
up-regulated in dormant phages [17-19]. Although Rv3628 
expression is not stress-related, one previous study showed 
that Rv3628 exhibited 4-fold greater expression in 
activated macrophages compared to resting macrophages 
[20]. A better understanding of the mycobacterial protein 
Rv3628 and its role in the host immune response may 
facilitate the rational design of more effective vaccines, 
such as multi-antigenic Mtb subunit vaccines.
Vaccine efficacy clearly depends on Mtb strain 
type [21]. In particular, the Mtb Beijing lineage is one 
of the most transmissible clades worldwide and exhibits 
epidemiological dominance in East Asia [22]. The Mtb 
K strain, which phylogenetically belongs to the Beijing 
lineage, was first isolated in South Korea in 1998, when 
a severe outbreak of pulmonary TB occurred in senior 
high schools [22]. This strain showed a highly virulent 
phenotype in a murine model of TB. This phenotype 
included rapid multiplication during the early stage of 
infection and excessive lung inflammation, and infection 
with this strain resulted in more rapid death of mice than 
infection with a reference H37Rv strain [22]. 
Overall, effective Ag targets for the rational design 
of Mtb vaccines should satisfy the following requirements: 
constitutive expression, accessibility (cell wall-associated 
or secreted) to Ag-presenting cells (APCs), ability to 
activate DCs, ability to be recognized by the immune 
system during in vivo infection, ability to induce a Th1-
biased memory immune response, and efficacy against 
hyper-virulent Mtb strains. In this study, we evaluated 
Rv3628, a vaccine candidate that fulfills these criteria 
and is effective against challenge with the highly virulent 
Mtb K strain. Additionally, we investigated the molecular 
details underlying the interactions formed between this Ag 
and DCs. 
rEsULts
Purification and cytotoxicity assay of recombinant 
rv3628
We first purified Rv3628 under endotoxin-free 
experimental conditions. To remove any contaminating 
endotoxins, the purified Rv3628 was exposed to 
polymyxin B agarose. The expected molecular weight 
of Rv3628 is approximately 19 kDa, and its size 
was confirmed by SDS-PAGE and Western blotting 
(Supplementary Figure S1A). Next, we examined whether 
Rv3628 is cytotoxic to DCs (Supplementary Figure S1B). 
Rv3628 was not cytotoxic to DCs at a concentration of 
10 μg/ml, indicating that a concentration below 10 μg/ml 
would not interfere with the subsequent experiments. 
Rv3628 protein induces functional and phenotypic 
maturation of DCs
To investigate whether Rv3628 protein induces 
DC activation, we first measured the expression of 
phenotypic markers of DC maturation by flow cytometry. 
To accomplish this, DCs were treated with either 
lipopolysaccharide (LPS, 100 ng/ml) as a positive control 
or Rv3628 (1 or 5 μg/ml) for 24 h. We found that Rv3628 
significantly augmented the expression of CD80, CD86, 
MHC class I molecules, and MHC class II molecules in 
a dose-dependent manner (Figure 1A). To examine the 
functional activation of DCs by Rv3628, we next examined 
the secretion of pro- and anti-inflammatory cytokines. 
Rv3628 significantly increased DC secretion of TNF-α, 
IL-6, IL-1β and IL-23 in a dose-dependent manner (Figure 
1B). We then investigated the production of IL-12p70 and 
IL-10, which stimulate the proliferation and development 
of Th1 and Th2 cells, respectively. Interestingly, Rv3628 
significantly induced the production of IL-12p70, but not 
that of IL-10 (Figure 1B and 1C). Because the capacity of 
DCs to take up an Ag (e.g., dextran) decreases during DC 
maturation after Ag recognition, we next investigated the 
role of Rv3628 in DC endocytosis. As shown in Figure 
1D, the endocytic activity of Rv3628-treated DCs was 
significantly decreased to a similar extent to that of LPS-
treated DCs. These experiments were repeated at 4°C, 
and the results showed that the uptake of dextran-FITC 
by DCs was inhibited at a low temperature. Thus, the 
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reduced endocytic activity of the Rv3628-treated DCs was 
indicative of their increased functional maturity. These 
results strongly indicate that Rv3628 phenotypically and 
functionally activates DCs and polarizes these cells toward 
a Th1 response.
Confirmation of LPS decontamination in purified 
Rv3628 samples
Because Rv3628-induced DC maturation may have 
resulted from contamination with LPS derived from E. 
Figure 1: Rv3628 induces DC maturation in a dose-dependent manner. Eight-day-old, immature DCs were treated with the 
indicated concentrations of Rv3628 or LPS for 24 h. A. DCs were stained with anti-CD80, anti-CD86, anti-MHC class I, or anti-MHC 
class II mAbs and analyzed for the expression of surface markers. The median fluorescence intensity (MFI) of the positive cells is shown 
for each panel. B. TNF-α, IL-6, IL-1β, IL-10, IL-23 and IL-12p70 levels in the culture medium were measured by ELISA. C. Dot plots 
of intracellular IL-12p70 and IL-10 in CD11c+ DCs. D. Endocytic activity was assessed at 37°C or 4°C by flow cytometric analysis of 
dextran-FITC uptake. The percentages of dextran-FITC-positive and CD11c+-positive cells are indicated. All bar graphs show the means ± 
SD of 3 samples. One representative plot out of three independent experiments is shown; *p < 0.05, **p < 0.01, and ***p < 0.001 for the 
treatments compared with untreated DCs (CON). 
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coli during protein preparation, we confirmed the lack of 
endotoxin contamination in the E. coli-derived Rv3628 
protein isolates using an Endpoint Chromogenic Limulus 
Amebocyte Lysate Assay kit (Lonza, Walkersville, 
MD, USA). We also assessed the effects of proteinase 
K pretreatment and heat denaturation. The levels of 
endotoxin in the Rv3628 preparations were < 15 pg/ml (< 
0.1 EU/ml, which is the lowest detectable level) (data not 
shown). Furthermore, proteinase K pretreatment and heat 
denaturation abrogated the ability of Rv3628 to trigger 
DC maturation (Supplementary Figure S2A and S2B). 
These results revealed that DC maturation was directly 
induced by intact Rv3628 and was not caused by potential 
endotoxin contamination.
Rv3628 induces DC activation by binding to 
TLR2 and activating the downstream MyD88 
signaling pathway
It is well known that the host immune response 
is initiated in response to interactions between pattern 
recognition receptors, such as TLRs, and pathogen-
associated molecular patterns (PAMPs) on secreted Mtb 
Ags and cell wall components [23]. Thus, we examined 
whether Rv3628 can be recognized by and act through 
TLRs in DCs. To identify the TLRs on DCs that interact 
with Rv3628, WT-, TLR2 KO-, and TLR4 KO-derived 
DCs were stimulated with Rv3628, and Rv3628 on the cell 
surface was detected with an Alexa488-conjugated anti-
His mAb. Rv3628 bound to the cell surface of WT- and 
TLR4 KO-derived DCs, but not that of TLR2 KO-derived 
DCs (Figure 2A). To confirm this interaction between 
Rv3628 and TLRs, we performed immunoprecipitation 
studies with TLR2 or TLR4 and Rv3628 in DCs. We 
found that Rv3628 bound to TLR2, but not to TLR4 
(Figure 2B). This result was confirmed by confocal 
microscopy, which showed that Rv3628 bound to TLR2 
molecules on the cell surface, but not to TLR4 molecules, 
as expected (Figure 2C). To further confirm the role of 
TLR2 in Rv3628-mediated DC maturation, we determined 
the expression of surface molecules and the production of 
cytokines in DCs isolated from WT, TLR2 KO and TLR4 
KO mice. We found that Rv3628 induced the expression 
of various surface molecules (Figure 2D) and augmented 
the secretion of pro-inflammatory cytokines (Figure 2E) 
in WT- and TLR4 KO-derived DCs compared to TLR2 
KO-derived DCs. 
Within the TLR family, TLR2, TLR3, TLR4, TLR7 
and TLR9 and their adaptor molecules MyD88 and 
TRIF play the most prominent roles in provoking innate 
immune responses [24]. Thus, MyD88 and TRIF have 
the potential to control various TLR-mediated signaling 
pathways. To investigate the relevance of the MyD88- and 
TRIF-dependent pathways to Rv3628-induced cytokine 
production by DCs, we compared cytokine secretion 
in WT-, MyD88 KO- and TRIF KO-derived DCs. As 
expected, the Rv3628-induced production of TNF-α, IL-
6, and IL-1β was significantly reduced in MyD88 KO 
mice, but not in TRIF KO mice (Figure 2F). Collectively, 
these data suggest that Rv3628-induced DC maturation 
is predominantly mediated via TLR2/MyD88-mediated 
signaling pathways.
Activation of the NF-κB and MAPK pathways 
mediates Rv3628-induced DC maturation
Next, we investigated the downstream pathways 
of TLR2-MyD88, specifically, the MAPK and NF-κB 
pathways, because these pathways play critical roles 
in mediating cellular responses [25]. We specifically 
hypothesized that the Rv3628-induced maturation 
of DCs involves the NF-κB and MAPK signaling 
pathways. As shown in Figure 3A, Rv3628 triggered the 
phosphorylation of MAPKs such as ERK, JNK, and p38 
MAPK in DCs. Moreover, we found that Rv3628 induced 
the phosphorylation and degradation of inhibitor of κB 
(IκB)-α and the nuclear translocation of p65 from the 
cytosol (Figure 3B and 3C). To understand the functional 
roles of these kinases in the Rv3628-induced activation 
of DCs, we used highly selective kinase inhibitors 
and examined their effects on Rv3628-induced DC 
maturation. In particular, DCs were pretreated for 1 h 
with or without inhibitors of p38, ERK1/2, JNK, or NF-
κB. As expected, we found that these pharmacological 
inhibitors significantly abrogated the Rv3628-induced 
expression of the co-stimulatory molecules CD80 and 
CD86 on the surfaces of DCs (Figure 3D) and augmented 
the production of pro-inflammatory cytokines such as 
TNF-α, IL-6, IL-1β and IL-12p70 (Figure 3E). These data 
suggest that the NF-κB and MAPK signaling pathways 
are critically important for optimal Rv3628-induced DC 
activation, triggering the secretion of pro-inflammatory 
cytokines and the expression of phenotypic markers for 
DC maturation. 
Rv3628-stimulated DCs enhance naïve T cell 
proliferation and favor Th1 polarization
The primary roles of mature DCs are Ag presentation 
and subsequent interactions with T cells, which induce 
T cell polarization [26]. To precisely characterize the 
effects of Rv3628 on the interactions that form between 
DCs and T cells, we performed a syngeneic T cell 
proliferation assay using OT-I T cell receptor (TCR)-
transgenic CD8+ T cells (OVA257-264) and OT-II TCR-
transgenic CD4+ T cells (OVA323-339). To accomplish this, 
CFSE-labeled OVA-specific CD4+ and CD8+ T cells were 
co-cultured with Rv3628-treated DCs and pulsed with 
OVA257-264 or OVA323-339. These treated cells proliferated 
to a considerably greater extent than identical T cells 
Oncotarget24966www.impactjournals.com/oncotarget
Figure 2: Rv3628 induces DC activation by interacting with TLR2. A. Bone marrow-derived DCs (BMDCs) from WT, TLR2 
KO, and TLR4 KO mice were treated with Rv3628 for 1 h and stained with an Alexa488-conjugated anti-His mAb. The MFI of the positive 
cells is shown in each panel. The bar graphs show the means ± SEM of the percentages of Rv3628-treated Alexa488-positive cells among 
the CD11c+ cells from three independent experiments. ***p < 0.001 compared with Rv3628-treated WT DCs. B. DCs were treated with 
Rv3628 for 6 h. The cells were harvested, and cell lysates were immunoprecipitated with anti-rat IgG, anti-mouse IgG, anti-His, anti-TLR2, 
or anti-TLR4. Proteins were visualized by immunoblotting with anti-His, anti-TLR2, or anti-TLR4 Abs. One representative plot out of three 
independent experiments is shown. C. Fluorescence intensities reflecting Rv3628 binding to Rv3628-treated DCs. DCs derived from WT, 
TLR2 KO, and TLR4 KO mice were treated with Rv3628 for 1 h, fixed, and stained with DAPI and a FITC-conjugated anti-Rv3628 Ab. 
One representative plot out of three independent experiments is shown. D. and E. DCs derived from WT, TLR2 KO, and TLR4 KO mice 
were treated with Rv3628 and LPS (100 ng/ml) for 24 h. The bar graphs show the regulation of surface molecules and pro-inflammatory 
cytokines among CD11c+-gated Rv3628-treated DCs derived from WT, TLR2 KO, and TLR4 KO mice. F. DCs derived from WT, MyD88 
KO, and TRIF KO mice were treated with Rv3628 and a MyD88-dependent TLR2 agonist (Pam3, 100 ng/ml) for 24 h. TNF-α, IL-6, and 
IL-1β production in Rv3628- or Pam3-treated DCs derived from WT, MyD88 KO, and TRIF KO mice was measured by ELISA. All data 
are expressed as the means ± SD of 3 samples. One representative plot out of three independent experiments is shown. **p < 0.01 and ***p 
< 0.001 compared with Rv3628-treated WT DCs. CON: untreated DCs; ISO: isotype control.
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Figure 3: Rv3628-dependent induction of DC maturation protein involves activation of the MAPK and NF-κB 
signaling pathways. A. and B. DCs treated with Rv3628 (5 μg/ml) for the indicated periods. Cell lysates were subjected to SDS-PAGE, 
and immunoblot analysis was performed using specific Abs against phospho-p38 (p-p38), p38, phospho-ERK1/2 (p-ERK1/2), ERK1/2, 
phospho-JNK (p-JNK), JNK, phospho-IκB-α (p-IκB-α), IκB-α, and p65 NF-κB. The results of one representative experiment out of three 
experiments producing similar results are shown. C. The effect of Rv3628 on the cellular localization of the p65 subunit of NF-κB in DCs. 
DCs were plated on glass chamber slides and treated with Rv3628 for 1 h. After Ag stimulation, the immunoreactivity of the p65 subunit of 
NF-κB in the DCs was analyzed by immunofluorescence, as described in the Materials and Methods section (original scale bar: 5 μm). The 
results of one representative experiment out of three experiments producing similar results are shown. D. and E. DCs were pretreated with 
different pharmacological inhibitors, such as SB203580 (p38 inhibitor), U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or Bay11-7082 
(NF-κB inhibitor) for 1 h prior to treatment with Rv3628 for 24 h; DMSO served as a vehicle control. D. CD80 and CD86 expression was 
analyzed by flow cytometry. E. TNF-α, IL-6, IL-1β and IL-12p70 levels in the culture medium were measured by ELISA. The data points 
shown are the means ± SD of 3 samples. One representative plot out of three independent experiments is shown; *p < 0.05, **p < 0.01 and 
***p < 0.001 compared to treatment with Rv3628 alone. CON: untreated DCs.
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co-cultured with non-Rv3628-treated DCs pulsed with 
OVA257-264 or OVA323-339 (Figure 4A). We then investigated 
the induction of cytokines (Figure 4B) and transcription 
factors (Figure 4C) in CD4+ and CD8+ T cells. IFN-γ and 
T-bet are expressed at high levels in Th1 cells, whereas 
IL-4 and GATA-3 are expressed at high levels in Th2 cells. 
As shown in Figure 4B and 4C, IFN-γ production and 
T-bet expression were both significantly higher in Rv3628-
treated DCs than in untreated DCs; however, the levels of 
IL-4 and GATA-3 were not affected. These results suggest 
Figure 4: Rv3628-treated DCs stimulate T cells to produce Th1 cytokines. T cell proliferation and T cell types were analyzed 
in OVA-specific mice as described in the Materials and Methods section. A. The proliferation of OVA-specific CD4+ and CD8+ T cells was 
assessed by flow cytometry. The results of one representative experiment out of three experiments producing similar results are shown. B. 
The culture supernatants obtained under the conditions described in part A were harvested after 24 h, and IFN-γ, IL-2 and IL-4 levels were 
analyzed by ELISA (top panel, OT-I; lower panel, OT-II). The data are shown as the means ± SD of 3 samples. One representative plot out 
of three independent experiments is shown. *p < 0.05, **p < 0.01, and ***p < 0.001 for comparisons with T cell/OVA257-264-pulsed DCs or 
T cell/OVA323-339-pulsed DCs. C. Western blot analysis of T-bet and GATA-3 expression in OVA-specific CD4+ T cells using specific anti-T-
bet and anti-GATA-3 mAbs. The results of one representative experiment out of three experiments producing similar results are shown. no 
OVA-DCs: untreated DCs; OVA-DCs: OVA-treated DCs; Rv3628-DCs: Rv3628-treated DCs; LPS-DCs: LPS-treated DCs.
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that Rv3628-treated DCs contribute to the polarization of 
naïve CD4+ and CD8+ T cells toward an IFN-γ-producing 
Th1-type T cell phenotype.
Rv3628-TLR2 binding in DCs is essential for the 
generation of effector/memory T cells
Ag-matured DCs promote memory T cell expansion, 
differentiation and activation [26]. Therefore, we 
Figure 5: Rv3628 induced Ag-specific effector/memory T cell expansion in the spleens of Mtb H37Rv-infected mice 
via TLR2 signaling. A. and B. WT-, TLR2 KO-, and TLR4 KO-DCs were treated for 24 h with Rv3628 (5 μg/ml) or Pam3 (100 ng/
ml). Untreated DCs, Rv3628-treated DCs (Rv3628-DCs) and Pam3-treated DCs (Pam3-DCs) were co-cultured for 3 days with T cells of 
H37Rv-infected mice at a DC to T cell ratio of 1:10. The T cells were stained with anti-CD4, CD8, CD62L, and CD44 mAbs. A. Contour 
and B. bar graphs show CD62L+CD44+T cell populations in the harvested spleen cells. Bar graphs show the percentages of effector/memory 
T cells (CD4+CD44+CD62L- and CD8+CD44+CD62L-) from one representative plot out of three independent experiments. The mean values 
± SD of 4 samples are shown. Statistical significance (**p<0.01 or ***p<0.001) is indicated for the different treatments compared to 
untreated DCs. 
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investigated whether DCs that underwent maturation 
following exposure to Rv3628 could specifically 
stimulate effector/memory CD4+ and CD8+ T cells 
isolated from the spleens of Mtb H37Rv-infected mice 
at 8 weeks post-infection. To accomplish this, we 
measured naïve T cell (CD44lowCD62Lhigh) and effector/
memory T cell (CD44highCD62Llow) subpopulations 
within CD4+ and CD8+ splenic T cell populations using 
flow cytometry. Splenic T cells collected from Mtb-
infected mice were co-cultured with Rv3628-treated 
DCs derived from WT-, TLR2 KO-, or TLR4 KO-mice. 
As shown in Figure 5A and B, the Rv3628-treated WT 
and TLR4 KO DCs specifically induced the formation 
of effector/memory T cells, as evidenced by the 
significant quantities of CD44highCD62LlowCD4+ T cells 
and CD44highCD62LlowCD8+ T cells identified within the 
treatment group compared to the no-treatment group. In 
contrast, these subpopulations were not observed in T cell 
populations that were co-cultured with Rv3628-treated 
TLR2 KO-DCs. Taken together, these findings suggest 
that the interactions that form between Rv3628 and TLR2 
are essential to the Rv3628-specific induction of effector/
memory T cells. 
Recognition of Rv3628 by the immune system 
during the course of Mtb infection
The immunobiological potential of Rv3628 as 
a potent Mtb Ag that can be recognized by T cells was 
further investigated by examining Rv3628-induced IFN-γ 
production and memory T cell expansion in the spleens 
and lungs of Mtb H37Rv- and K-infected mice at various 
time points. Given that ESAT-6, which is produced 
by Mtb, is a representative T cell Ag in both mice and 
humans during infection [27], we used ESAT-6 as a 
positive control for the measurement of T cell activation 
and memory T cell generation in the Mtb-infected mice. 
As shown in Figure 6A, lung and spleen cells from both 
Mtb H37Rv- and K-infected mice showed significant 
IFN-γ production in response to Rv3628 or ESAT-6 
stimulation. Next, the populations of memory T cells that 
were generated following stimulation with Rv3628 were 
analyzed by flow cytometry using a gating strategy (Figure 
6B). Importantly, the lung and spleen cells that were 
stimulated with Rv3628 showed comparable levels of 
effector/memory T cell expansion, regardless of the Mtb 
strain used for infection (Figure 6C). These data suggest 
that Rv3628 is immunologically recognized during Mtb 
infection, causing a potent T cell response.
Rv3628 immunization and analysis of 
immunogenicity
The above results regarding Rv3628-mediated 
induction of T cell proliferation and Th1 response-
mediated immunity motivated us to test the vaccine 
efficacy of Rv3628 following challenge with the highly 
virulent Mtb strain known as Beijing-K. Prior to this 
in vivo experiment, we investigated whether Rv3628 
functions as an immunogenic protein when administered as 
an Ag in a subunit vaccine. For this purpose, we evaluated 
the induction of IFN-γ production, the generation of IFN-
γ-producing T cells and Rv3628-specific IFN-γ-producing 
T cells, and the production of Ag-specific antibodies 
following immunization with a vaccine consisting of 
Rv3628 adjuvanted with MPL-DDA (Figure 7 and 
Supplementary Figure S3). To accomplish this, lung and 
spleen cells from an immunized mouse (immunized with 
MPL-DDA, BCG or Rv3628/MPL-DDA) were stimulated 
with Rv3628 at various doses (0.2, 1 or 5 μg/ml). We 
found that IFN-γ production significantly increased in the 
groups that were immunized with Rv3628/MPL-DDA 
upon cognate Rv3628 stimulation (1 μg/ml [p < 0.001] or 
5 μg/ml [p < 0.001]) compared with the MPL-DDA-only 
groups (Figure 7B). Next, populations of IFN-γ-producing 
CD4+ T cells (panel a in Figure 7C) and Rv3628-specific 
IFN-γ-producing CD4+ T cells (panel b in Figure 7C) 
were restimulated with Rv3628 at a concentration of 5 μg/
ml and then analyzed by flow cytometry using a gating 
strategy. IFN-γ-producing CD8+ T cells and Rv3628-
specific IFN-γ-producing CD8+ T cells were also analyzed 
using the same gating strategy as in Figure 7C (data not 
shown). This restimulation significantly increased the 
subpopulations of IFN-γ-producing T cells (CD4+/IFN-γ+ 
and CD8+/IFN-γ+ cells, Figure 7D) and Ag-specific IFN-γ-
producing T cells (CD4+/CD44+/IFN-γ+ and CD8+/CD44+/
IFN-γ+ cells, Figure 7E) in the spleens and lungs of the 
Rv3628-immunized mice compared to the non-Rv3628-
stimulated mice. Further analysis of Rv3628-specific 
antibody titers showed that the mice in the Rv3628-
immunized groups exhibited significant Rv3628-specific 
IgG2c responses, but not IgG1 responses (Supplementary 
Figure S3). These results indicate that immunization 
with Rv3628 induces the development of effective Th1 
immunity. Additionally, the BCG-immunized groups 
showed augmented IFN-γ release (Figure 7B) and 
increased populations of IFN-γ-producing T cells (Figure 
7D) in response to stimulation with Rv3628 (5 μg/ml). 
Protective efficacy of the Rv3628 subunit vaccine 
against challenge with the Mtb K strain in a 
mouse model
We next assessed the level of protection that 
was generated against challenge with the Mtb K strain 
following immunization with Rv3628. To accomplish this, 
three weeks after the third immunization, the mice were 
challenged with an aerosol of the highly virulent Mtb K 
strain. At 4 and 9 weeks post-challenge, the MPL-DDA-, 
BCG- and Rv3628/MPL-DDA-immunized groups were 
Oncotarget24971www.impactjournals.com/oncotarget
Figure 6: Ex vivo-stimulated Rv3628 induces Ag-specific IFN-γ production and memory T cell expansion in spleen 
and lung cells after challenge with Mtb strains. A. Rv3628-specific IFN-γ production was analyzed in the spleen and lung cells of 
individual mice 4 and 8 weeks after challenge with aerosolized Mtb H37Rv or K. ESAT-6 was used as a positive control. The bar graphs 
show the means ± SD of 4 samples. One representative plot out of three independent experiments is shown. *p < 0.05, **p < 0.01, and 
***p < 0.001. non: untreated cells; ESAT-6: ESAT-6-treated cells; Rv3628: Rv3628-treated cells. B. For the analysis of memory T cells, 
an inclusion gate was drawn around cells with equivalent forward scatter-height and forward scatter-area values to exclude doublets and 
larger cell aggregates (data not shown). CD4+ T cells were then gated based on their makers (CD3 and CD4), and these cells were further 
gated for naive cells (a: CD62L+CD127+CD44-), central memory cells (b: CD62L+CD127+CD44+), effector memory cells (c: CD62L-
CD127+CD44+), and effector cells (d: CD62L-CD127-CD44+) within the CD3+CD4+ T cell population. C. At the same time point, spleen 
and lung cells were stimulated in vitro with Rv3628, and the numbers of naïve CD4+ T cells, effector CD4+ T cells, central memory CD4+ 
T cells and effector/memory CD4+ T cells were analyzed by flow cytometry. The data are expressed as the means ± SD of 4 samples from 
one representative experiment out of three independent experiments. Statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) is 
shown for the treated cells compared to the non-treated effector/memory T cells. NI: non-infected mice, H37Rv: H37Rv-infected mice, K: 
K-infected mice.
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Figure 7: Ag-specific responses in spleen and lung cells after final immunization with MPL-DDA alone, BCG or 
Rv3628/MPL-DDA. A. Schematic diagram of the experimental design. B. IFN-γ production by spleen and lung cells in response 
to Rv3628 stimulation was measured by ELISA. **p < 0.01 and ***p < 0.001 compared with the MPL-DDA-alone group C. to E. 
Staining panel and gating strategy used to identify IFN-γ-producing T cells (panel a) and Ag-specific IFN-γ-producing T cells (panel b) in 
spleen and lung cells from representative mice immunized with MPL-DDA, BCG or Rv3628/MPL-DDA. CD4+ and CD8+ T cells were 
identified based on CD3, CD4 and CD8 expression. Subsequently, IFN-γ-producing T cells (D: CD3+CD4+IFN-γ+ and CD3+CD8+IFN-γ+) 
and Ag-specific IFN-γ-producing T cells (E: CD3+CD4+CD44+IFN-γ+ and CD3+CD8+CD44+IFN-γ+) were gated as shown. *p < 0.05, **p 
< 0.01, and ***p < 0.001 compared with the Rv3628/MPL-DDA or BCG-immunized group. All graphs show the results from one of two 
experiments producing similar results (n = 6 animals/group). 
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histologically examined (Figure 8A and Supplementary 
Figure 4), and their bacterial burdens were quantified 
(Figure 8B). At 9 weeks post-challenge, the Rv3628/
MPL-DDA-immunized group showed significantly 
reduced lung inflammation compared with the infection 
control group (p < 0.01); however, a lesser degree of 
pathological improvement following Rv3628 vaccination 
was observed at 4 weeks post-challenge compared to 
9 weeks post-challenge (Supplementary Figure 4). In 
addition, compared with the infection control groups, the 
Rv3628-immunized mice exhibited significantly reduced 
bacterial burdens in the lungs and the spleen at 4 and 9 
weeks post-challenge (Figure 8B). 
Figure 8: Histology of representative lung lobes and CFU values for each group. A. Lung sections from each immunized 
mouse (immunization with MPL-DDA alone, BCG alone or Rv3628/MPL-DDA) were stained with H&E at 9 weeks after challenge with 
Mtb K. B. Differences in bacterial burden among mice immunized with BCG alone, Rv3628/MPL-DDA and those treated with the adjuvant 
control (MPL-DDA alone) at 4 and 9 weeks after challenge with Mtb K are shown. The results from one of two experiments producing 
similar results are shown (n = 6 animals/group). *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the MPL-DDA-alone group.
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Maintenance of Rv3628-specific Th1 immune 
responses in mice infected with Mtb Beijing-K
Th1-mediated immune responses and 
multifunctional T cells play important roles in generating 
protective immunity against Mtb [28, 29]. Therefore, we 
next evaluated how immunization with Rv3628 affected 
the T cell phenotype. At 4 and 9 weeks post-challenge, 
spleen and lung cells were stimulated in vitro with Rv3628, 
and the phenotypes of the responding CD4+ and CD8+ T 
cells were evaluated by multicolor intracellular cytokine 
staining and flow cytometry (Figure 9A). At 4 and 9 weeks 
Figure 9: Rv3628/MPL-DDA induces the production of multifunctional CD4+ T cells. A. and B. Cytokine production by 
Rv3628-specific CD4+ T cells in immunized mice (n = 6 animals/group) was analyzed at 4 and 9 weeks after challenge with Mtb K using 
flow cytometry. A. The strategy for gating multifunctional CD4+ T cells is shown for a representative mouse immunized with Rv3628/
MPL-DDA. B. Spleen and lung cells from immunized mice were stimulated with Rv3628 (5 μg/ml) for 12 h in the presence of GolgiStop. 
Rv3628-stimulated cells were identified by intracellular cytokine staining based on CD3, CD4 and CD8 expression and were further 
gated for CD44+ cells. The percentages of cells expressing all three cytokines (IFN-γ, TNF-α, and IL-2), two of these three cytokines, or 
one of these three cytokines in each group are depicted in the bar graphs (B, left panel) and pie charts (B, right panel). The results of one 
representative study out of at least two independent studies are presented. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the 
MPL-DDA-alone group (unpaired t-test).
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post-challenge, increased levels of triple-positive CD4+ 
T cells (co-expressing IFN-γ, TNF-α and IL-2), but not 
CD8+ T cells, were observed in the spleens and lungs of 
the Rv3628-immunized group compared with the infection 
control group (Figure 9B and Supplementary Figure S5). 
In addition, the Rv3628-immunized group showed higher 
populations of double-positive multifunctional CD4+ T 
cells (IFN-γ+TNF-α+CD4+ and TNF-α+IL-2+CD4+ T cells) 
in the lung at 4 and 9 weeks post-challenge (Figure 9B), 
but this phenomenon was not observed for CD8+ T cells 
(Supplementary Figure S5). 
CD4+ T cell types induced by Rv3628 vaccination 
in mice infected with Mtb Beijing-K
Recent studies have shown that the development 
of Th1 and Th17 immune responses induces protection 
against TB [30]. In the present study, at 4 and 9 weeks 
post-challenge, T-bet-expressing CD4+ T cells (Th1-type 
cells), GATA-3-expressing CD4+ T cells (Th2-type cells) 
and RORγt-expressing CD4+ T cells (Th17-type cells) 
were evaluated by transcription factor staining and flow 
cytometry (Supplementary Figure S6A). T-bet-expressing 
CD4+ T cells were observed in the spleens and lungs of the 
Rv3628-immunized mice at 4 and 9 weeks post-challenge 
(Supplementary Figure S6B). Interestingly, immunization 
with Rv3628 induced the production of both T-bet-
expressing CD4+ T cells and RORγt-expressing CD4+ T 
cells in the lung, but not in the spleen (Supplementary 
Figure S6B). 
DIscUssION
In the current study, we first evaluated the functional 
roles assumed by Rv3628 when interacting with DCs. We 
found that Rv3628 acts as a selective agonist of TLR2 
in DCs and functionally induces DC maturation by 
elevating the expression of cell surface molecules and the 
production of Th1-polarizing pro-inflammatory cytokines 
in DCs via the activities of the MyD88-, MAPK-, and NF-
κB-dependent signaling pathways (Figures 1, 2 and 3). 
Furthermore, Rv3628 participates in adaptive immunity 
by shifting induced naïve T cell immune responses toward 
Th1 polarization (Figure 4). Although several previous 
reports have described the roles of TLR2 agonists 
produced by Mtb [30-32], to the best of our knowledge, 
this is the first time that the Mtb protein Rv3628 has been 
described as a TLR2 agonist.
In general, Mtb Ags that serve as TLR2 agonists—
either as immune activators or as virulence factors—
should be considered for inclusion in novel TB vaccines 
if they are recognized by the immune system [30-32]. For 
example, Mtb can expropriate the TLR2 signaling pathway 
to subvert host immunity by attenuating macrophage 
responses to IFN-γ, which suppresses Ag processing and 
presentation [33, 34]. Importantly, Rv1196, Rv1917c, 
and PPE18 have all been reported to interact with TLR2 
molecules on macrophage and DC surfaces and to strongly 
induce the secretion of IL-10, which is known to favor 
a Th2 immune response [35, 36]. This immune response 
potentially serves as an immune evasion mechanism by 
blunting protective Th1 immunity against Mtb infection. 
As another example, the same group reported that LprG 
(Rv1411c) inhibits human macrophage-mediated MHC 
class II Ag processing, suppressing Ag recognition 
by CD4+ T cells [37]. However, Rv1196 and PPE18 
are both components of the MF72F vaccine, which 
is currently under investigation in a Phase II clinical 
study. Furthermore, an Rv1411/ESAT-6 fusion protein 
has been shown to enhance vaccine efficacy in the 
absence of additional Th1 response-inducing adjuvants, 
indicating that this protein has natural adjuvanticity due 
to its interaction with TLR2 [32, 38, 39]. Alternatively, 
the Mtb Ag TB10.4, which is a TLR2 agonist, induces 
a strong Th1 response mediated by CD4+ T cells and 
displays good vaccine potential [40], and ESAT-6, the 
most fully characterized immunogenic Mtb Ag, promotes 
protective Th1 and Th17 responses in a TLR2-dependent 
manner [31]. These two Ags (TB10.4 and ESAT-6) are 
secreted during the infection course, and their common 
features are recognized by the host immune system [31, 
40]. Thus, gaining an understanding of the cross-talk that 
forms between TLR2 and Mtb Ags will impact the design 
of novel therapeutic strategies and the development of 
vaccines and immunotherapy regimens. 
Bertholet et al. specifically identified Rv3628 as a 
human T cell Ag [41]. When PBMCs from PPD-negative 
and PPD-positive healthy subjects were examined, 
Rv3628 was found to stimulate the PBMCs from all of the 
PPD-positive subjects, but not the PBMCs from any of the 
PPD-negative subjects. Additionally, an elevated IFN-γ 
recall response was observed in the Rv3628-stimulated 
PBMCs from the PPD-positive subjects [41]. In our study, 
IFN-γ production (Figure 6A) and CD4+ memory T cell 
expansion (Figure 6C) were observed in spleen and lung 
cells isolated from mice treated with Rv3628 at various 
time points after infection with Mtb strains (H37Rv and 
Beijing-K). 
Interestingly, the protective efficacy induced by 
Rv3628 adjuvanted with CpG, a TLR9 agonist, was 
unexpectedly low in a murine TB model [41]. The MyD88 
signaling pathway, which functions downstream of the 
adjuvant CpG, is shared by Rv3628. Importantly, a recent 
study showed that co-activation of the MyD88 and TRIF 
signaling pathways is an important mechanism supporting 
the development of sustained vaccine-induced protective 
T cell immunity against Mtb infection [42]. Thus, utilizing 
an Ag and an adjuvant that share the same signaling 
pathway may not be advantageous in TB subunit vaccine 
development, and an understanding of the nature of the 
Ag is important. 
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In the current study, we employed MPL as an 
adjuvant for the Rv3628 subunit vaccine. MPL appears to 
enable potent but safe adjuvanticity as a result of TRIF-
biased signaling [43]. However, TRIF-biased TLR4 
activation by MPL may not produce a maximal Th1 
immune response. Indeed, synergistic interactions between 
MyD88 and TRIF are required for Th1 cell polarization 
by a TLR4-based adjuvant [44]. Accordingly, activation 
of both the MyD88 (by Rv3628) and TRIF (by MPL) 
signaling pathways may be essential for the protective 
efficacy of the Rv3628 subunit vaccine by enhancing Th1-
biased immune responses against aerosol challenge with 
Mtb. In this context, the activation of both the MyD88 and 
TRIF signaling pathways is essential for effective adjuvant 
activity when an Ag displays self-adjuvanticity [44]. Thus, 
choosing an appropriate adjuvant or delivery platform is 
critical to the success of a subunit vaccine. 
In general, high CD44 expression on T cell 
surfaces is considered to indicate that the T cells are 
antigen-experienced (i.e., they exhibit an antigen-specific 
effector/memory phenotype) [45]. In addition, a recent 
study showed that CD44 is essential to the generation 
and maintenance of memory T helper 1 (Th1) cells [46]. 
Interestingly, Rv3628/MPL-DDA-immunized mice 
showed increased populations of IFN-γ+CD44+ T cells 
(Figure 7E). Based on these results, we investigated the 
protective effect of the Rv3628/MPL-DDA vaccine against 
the Mtb K strain, a hyper-virulent W-Beijing-lineage 
strain, in a mouse model. Rv3628/MPL-DDA-immunized 
mice were substantially protected after challenge with 
the Mtb K strain based on assessments of lung pathology 
(Figure 8A and Supplementary Figure S4) and bacterial 
growth (Figure 8B). 
Importantly, vaccine-induced protection against Mtb 
infection specifically involves the presence of Ag-specific 
multifunctional IFN-γ+TNF-α+IL-2+ and IFN-γ+TNF-α+ 
CD4+ T cells in the lungs [28, 47]. Additionally, Khader et 
al. showed that the induction of host-mediated Ag-specific 
IFN-γ and IL-17 responses induces significant protection 
against aerogenic challenge with both highly susceptible 
and highly resistant Mtb strains [48]. Importantly, 
an examination of Ag-immunized mice showed that 
immunization with Rv3628 significantly induced the 
production of multifunctional CD4+ T cells (Figure 9) in 
the lungs and the spleen following challenge with the Mtb 
K strain. Interestingly, CD4+ T cells from BCG-immunized 
mice showed weaker responses to Rv3628 than CD4+ T 
cells from Rv3628-immunized mice. However, the BCG-
immunized mice showed substantial reductions in bacterial 
growth (slightly better than the Rv3628-immunized mice) 
despite the milder induction of Rv3628-specific T cell 
immunity compared to the Rv3628-immunized mice 
(Figure 8B and Figure 9B). These results suggest that 
BCG contains many Ags that can augment multifunctional 
T cell populations. In addition, the Rv3628-immunized 
mice exhibited early induction of T-bet+CD4+ T cells (Th1 
cells) and RORγt+CD4+ T cells (Th17 cells) in the lungs 
following challenge with the Mtb K strain (Supplementary 
Figure S5). Based on these trends, Rv3628 can likely 
function as a central component of a successful vaccine 
against Mtb infection.
  In summary, our data show that the Rv3628 
protein plays a critical role in DC activation in a TLR2-
dependent manner and induces the adaptive immune 
response by specifically promoting the development 
of naïve CD4+ T cells and the expansion of Ag-specific 
memory CD4+ T cells. Importantly, immunization with 
Rv3628 conferred protective immunity and imparted 
significant protection to mice infected with the Mtb K 
strain, indicating that Rv3628 is a potential candidate 




All animal studies were performed in accordance 
with Korean Food and Drug Administration (KFDA) 
guidelines. The experimental protocols used in this study 
were reviewed and approved by the Ethics Committee 
and Institutional Animal Care and Use Committee 
(Permit Number: 2014-0197-3) of the Laboratory Animal 
Research Center at Yonsei University College of Medicine 
(Seoul, Korea).
Animals
Wild-type (WT), Toll-like receptor (TLR) 2 
knockout (KO), TLR4 KO, OT-I and OT-II T cell receptor 
(TCR) transgenic mice (C57BL/6 background) were 
purchased from Jackson Laboratory (Bar Harbor, ME, 
USA) and were maintained under barrier conditions in a 
BL-3 biohazard animal facility at the Yonsei University 
Medical Research Center in an environment with a 
constant temperature (24±1°C) and humidity (50±5%). 
The animals were fed a sterile commercial mouse diet and 
were provided with water ad libitum under standardized 
light-controlled conditions (12-h light and dark periods). 
The mice were monitored daily, and none of the mice 
exhibited any clinical symptoms or illness during the 
experimental period.
Purification of recombinant Rv3628 protein from 
Escherichia coli
To produce recombinant Rv3628 protein, the 
corresponding gene was amplified by PCR using Mtb 
H37Rv ATCC 27294 genomic DNA as a template and the 
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primer sequences 5’-CAATTCGACGTGACCATCGAA-3’ 
and 3’-GTGTGTACCGGCCTTGAAGCG-5’. The 
rv3628 gene was inserted into a pET22b (+) plasmid 
(Novagen, Madison, WI), and the resultant products were 
sequenced. Plasmids containing recombinant Rv3628 
were transformed into E. coli BL21 cells by heat-shock 
for 1 min at 42°C. After cell disruption via sonication, 
recombinant Rv3628 was purified using Ni-NTA resin 
as previously described with slight modifications [8]. To 
remove endotoxins, the dialyzed recombinant protein was 
incubated with polymyxin B-agarose (Sigma, St. Louis, 
MO, USA) for 6 h at 4°C. Finally, the purified endotoxin-
free recombinant protein was filter-sterilized and frozen 
at -70°C. The protein concentration was estimated using a 
bicinchoninic acid protein assay kit (Pierce, Rockford, IL, 
USA) with bovine serum albumin as a standard. 
Generation and culture of DCs
Bone marrow-derived DCs (BMDCs) were prepared 
and cultured as previously described [8]. On day 8, over 
80% of nonadherent cells expressed CD11c. To obtain 
highly purified cell populations for subsequent analyses, 
the DCs were labeled with a bead-conjugated anti-CD11c 
mAb (Miltenyi Biotec, Bergisch Gladbach, Germany), 
followed by positive selection on paramagnetic columns 
(LS columns; Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. 
The purity of the selected cell fraction was > 90%. 
Cytotoxicity analysis and Ag uptake assay
To investigate the cytotoxic effect of Rv3628 on 
the DCs, Rv3628 (5 μg/ml) was added to cultures of 
isolated DCs (1 × 106 cells/ml), and DC cell death was 
analyzed. After 24 h of treatment, the DCs were harvested, 
washed with PBS and stained with FITC-Annexin V 
and propidium iodide (BD PharMingen, San Jose, CA, 
USA). Thereafter, DC cytotoxicity was analyzed using 
a FACSverse flow cytometer (Becton Dickinson, San 
Jose, CA, USA). The Ag-uptake ability of the DCs was 
determined according to a procedure reported by Kim et 
al. [8].
Flow cytometry analysis of cell surface molecule 
expression
On day 8, the BMDCs were harvested, washed 
with PBS, and resuspended in fluorescence-activated cell 
sorter washing buffer (2% FBS and 0.1% sodium azide 
in PBS). The cells were stained with PE-labeled anti-H-
2Kb (MHC class I) and anti-I-Ab (MHC class II), APC-
labeled anti-CD80 and anti-CD86, and PE-Cy7-labeled 
anti-CD11c from eBioscience (San Diego, CA, USA) for 
45 min at 4°C. The cells were washed three times with 
PBS and resuspended in PBS. The resulting fluorescence 
was measured via flow cytometry using FlowJo software 
(BD Biosciences). LPS (100 ng/ml) was used as a positive 
control for DC maturation.
Cytokine assays
A sandwich enzyme-linked immunosorbent assay 
(ELISA) was used to detect IL-6, IL-1β, TNF-α, IL-12p70, 
IL-10, IL-17A, IL-4, IL-23 (eBioscience) and IFN-γ (BD 
Biosciences) levels in culture supernatants as previously 
described [7]. 
Flow cytometric analysis and intracellular 
cytokine staining
To create single-cell suspensions, harvested spleens 
and lungs were incubated in RPMI 1640 digestion 
media (10% fetal bovine serum, 0.1% collagenase type 
II (Worthington), 1 mM MgCl2, and 1 mM CaCl2) at 
37°C for 30 min. The single-cell suspensions were then 
filtered through a 40-µm cell nylon mesh cell strainer, 
treated with RBC lysis buffer (Sigma) for 5 min, and 
washed twice with RPMI 1640 medium supplemented 
with 2% FBS. Single-cell suspensions from the spleens 
and the lungs of immunized mice were stimulated with 
Rv3628 (5 μg/ml) for 12 h at 37°C in the presence of 
GolgiStop (eBioscience). The cells were first blocked 
with Fc Block (anti-CD16/32; eBioscience) for 15 min 
at 4°C and then stained with fluorochrome-conjugated 
antibodies against CD4, CD8, CD62L, CD44, CD127 
(eBioscience) and CD3 (BD bioscience) for 30 min at 
4°C. Cells stained with appropriate isotype-matched 
immunoglobulins were used as negative controls. The cells 
were fixed and permeabilized using a Cytofix/Cytoperm 
kit (BD Biosciences) according to the manufacturer’s 
instructions. Intracellular TNF-α, IL-2, T-bet, GATA-3, 
RORγt (eBioscience) and IFN-γ (BD bioscience) levels 
were detected with fluorescein-conjugated antibodies 
in a permeation buffer. The cells were analyzed with a 
FACSverse flow cytometer using FlowJo software.
Immunoprecipitation
DCs (1 × 107) were incubated in Rv3628 (10 μg/
ml) for 6 h, and the cells were then pelleted and lysed 
with Pierce immunoprecipitation lysis buffer (Rockford, 
IL, USA). The cell lysates were then pre-cleared with 
protein A or G Sepharose beads for 2 h at 4°C overnight 
with rotation. Rv3628 and TLR2- and TLR4-associated 
proteins were immunoprecipitated by incubation in protein 
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A or G Sepharose for 24 h at 4°C after incubation with 
control antibodies (Abs) for 1 h at 4°C: anti-rat IgG served 
as a control for anti-TLR2 and anti-TLR4 monoclonal 
Abs (mAbs), and anti-mouse IgG served as a control 
for the anti-His mAb (Santa Cruz Biotechnology). The 
beads were harvested, washed and boiled in 5X sample 
buffer for 5 min. Proteins were separated via 10% SDS-
PAGE followed by transfer to polyvinylidene difluoride 
membranes (Millipore). The membranes were further 
probed with anti-TLR2, ant-TLR4, and anti-His Abs as 
indicated.
Confocal laser scanning microscopy
WT-, TLR2 KO- and TLR4 KO-derived DCs 
were incubated overnight on poly-L-lysine-coated glass 
coverslips. After treatment with Rv3628, the cells were 
fixed in 4% paraformaldehyde, permeabilized in 0.1% 
Triton X-100, and blocked with 2% bovine serum albumin 
(BSA) in PBS containing 0.1% Tween-20 (PBS/T) for 2 h 
before incubation in 2% BSA in PBS/T containing an anti-
His Ab for 2 h at room temperature. After washing with 
PBS/T, the cells were incubated with a FITC-conjugated 
secondary antibody in a dark room for 1 h and then stained 
with 1 μg/ml DAPI for 10 min at room temperature. Cell 
morphology and fluorescence intensity were observed 
using a confocal laser scanning microscope (Zeiss 
LSM510 Meta). Images were acquired using LSM510 
Meta software and processed using an LSM imager. 
Immunoblotting analysis
After stimulation, cells were lysed in 100 ml of 
Pierce RIPA buffer supplemented with protease inhibitor 
cocktail. Immunoblotting was performed as previously 
described [8]. 
Nuclear extract preparation
Nuclear extracts from cells were prepared as 
follows. Cells were treated with 100 ml of lysis buffer 
[10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 
0.5% Nonidet P-40, 1 mM dithiothreitol (DTT), and 0.5 
mM PMSF] on ice for 10 min. After centrifugation at 
4000 rpm for 5 min, the pellet was resuspended in 100 ml 
of extraction buffer [20 mM HEPES (pH 7.9), 400 mM 
NaCl, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF] and 
incubated on ice for 30 min. After centrifugation at 12,000 
rpm for 10 min, the supernatant containing the nuclear 
extracts was collected and stored at -80°C until use.
Treatment of DCs with pharmacological 
inhibitors of signaling pathways
All pharmacological inhibitors used in this study 
were purchased from Calbiochem (San Diego, CA, USA). 
Dimethyl sulfoxide (Sigma) was added to the cultures at 
a 0.1% vol./vol. concentration as a solvent control. DCs 
were washed with PBS and pretreated with inhibitors in 
RPMI 1640 medium containing glutamine for 1 h prior to 
treatment with Rv3628 (5 μg/ml) for 24 h. The inhibitors 
were used at the following concentrations: U0126, 10 
μM; SB203580, 20 μM; SP600125, 10 μM; and Bay11-
7082, 20 μM. For all experiments involving inhibitors, 
the inhibitor concentration used was selected after careful 
titration experiments and assessments of DC viability 
using MTT assays. 
In vitro T cell proliferation assay
Responder T cells, which participate in allogeneic T 
cell reactions, were isolated from total mononuclear cells 
prepared from mouse spleens using a magnetic-activated 
cell sorting column. OVA-specific CD8+ and CD4+ T cells, 
which were classified as responder T cells, were obtained 
from the spleens of OT-I and OT-II mice, respectively. 
These T cells were stained with 1 μM CFSE (Invitrogen). 
DCs (2 × 105 cells per well) treated with OVA peptide in 
the presence of 1 or 5 μg/ml Rv3628 for 24 h were co-
cultured with CFSE-stained CD8+ and CD4+ T cells (2 × 
106) at a DC:T cell ratio of 1:10. On day 3 of co-culture, 
each T cell culture was stained with a Percp-Cy5.5-
conjugated anti-CD4 or anti-CD8 Ab (eBioscience) and 
then analyzed using a flow cytometer. The supernatants 
were harvested, and cytokine production was analyzed by 
ELISA.
Confirmation of lipopolysaccharide 
decontamination in Rv3628 samples
To characterize the physical and chemical nature of 
Rv3628, the isolate was heated for 15 min at 100°C or 
digested for 1 h at 37°C with soluble proteinase K (Sigma) 
at 5 μg/ml with Rv3628. After 24 h, the TNF-α and IL-6 
levels in the BMDC supernatant were analyzed using 
ELISA. 
In vivo experiments, vaccination and challenge in 
mice
We performed animal infection studies to address 
two specific aims: 1) to investigate whether Rv3628 is 
immunologically recognized in the lungs and spleens 
of Mtb-infected mice during early and late infection, 
and 2) to investigate whether the Rv3628 subunit 
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vaccine is effective against challenge with the hyper-
virulent Beijing strain. To address these questions, we 
conducted animal experiments with Mtb H37Rv and/
or Mtb Beijing-K at various time points post-infection. 
For aim #1, lung and spleen cells collected from Mtb 
H37Rv- or Mtb Beijing-K-infected mice at 4 and 8 weeks 
post-infection were stimulated with Rv3628 or 6-kDa 
early secretory antigenic target (ESAT-6; 5 μg/ml). Ex 
vivo-stimulated Rv3628-specific IFN-γ production and 
memory T cell expansion were then assessed as described 
above. For aim #2, the efficacy of the Rv3628 vaccine 
was compared with that of the BCG vaccine. Adjuvant 
control groups were immunized subcutaneously with 
dimethyldioctadecylammonium (DDA) liposomes (50 
μg/injection) containing monophosphoryl lipid-A (MPL, 
5 μg/injection) three times at 3-week intervals. MPL and 
DDA were purchased from Sigma-Aldrich (St. Louis, 
MO). For Rv3628 vaccination, mice were immunized 
subcutaneously three times at 3-week intervals with a 
formulation containing Rv3628 (5 μg) and MPL-DDA. 
The BCG-vaccinated groups were subcutaneously 
challenged one time with 2.0×105 CFU of BCG Pasteur 
1173P2 at the time of the 2nd injection of the Rv3628/MPL-
DDA vaccine. Three weeks after the final immunization, 
spleen and lung cells were harvested and used to 
investigate immunogenicity (i.e., IFN-γ secretion and 
populations of IFN-γ-producing T cells and Ag-specific 
IFN-γ-producing T cells). To study the protective efficacy 
of Rv3628, adjuvant-only (MPL-DDA) and Rv3628/
MPL-DDA groups were challenged with an aerosol of 
the Mtb K strain as previously described [22]. Briefly, the 
mice were exposed to a predetermined dose of the Mtb K 
strain for 60 min in the inhalation chamber of an airborne 
infection apparatus (Glas-Col, Terre Haute, IN, USA) to 
expose the mice to approximately 200 CFU of viable Mtb. 
At 4 and 9 weeks post-challenge, spleen and lung cells 
were harvested from each group, and multifunctional T 
cells and T cell subtype populations were assessed using 
flow cytometry.
Antibody titers in serum
Rv3628-specific IgG1 and IgG2c titers in serum 
were measured as an indicator of antigen-specific type 1 
or type 2 immune responses, respectively. Briefly, plates 
were coated with 2 μg/ml of Rv3628, and HRP-conjugated 
antibodies against IgG1 or IgG2c were used as secondary 
antibodies. After stopping the reaction, the plates were 
read within 30 min at 495 nm in a microplate ELISA 
reader with a cut-off optical density value of 0.1.
Bacterial counts and histopathology
The numbers of viable bacteria in the lungs and the 
spleens of the mice were evaluated as previously described 
[22]. Briefly, the bacterial count in each organ was 
determined by plating organ homogenates on Middlebrook 
7H10 agar (Becton Dickinson, Franklin Lakes, NJ, USA) 
supplemented with 10% OADC enrichment medium until 
the late exponential phase. CFU counts were performed 
after 4 weeks of incubation at 37°C. Lung samples 
collected for histopathology were preserved overnight in 
10% normal buffered formalin, embedded with paraffin, 
sliced into 4- to 5-mm-thick sections, and stained with 
hematoxylin-eosin (H&E). The superior lobes of the 
right lung were stained with H&E to assess the severity 
of inflammation. The level of inflammation in the lungs 
was evaluated using ImageJ software (National Institutes 
of Health, USA) as previously described [49].
Statistical analysis
All in vitro experiments were repeated at least 3 
times and produced consistent results. The data in the 
graphs are expressed as the means ± standard deviation. 
The data from the in vivo experiments are reported as the 
medians ± interquartile range (IQR). The significance 
of differences between two groups was determined 
using unpaired Student’s t-tests, and the significance of 
differences between three or more groups was evaluated 
with one-way ANOVA followed by Dunnett’s multiple 
comparison test using statistical software (GraphPad Prism 
Software, version 5.01; San Diego, CA, USA). *p < 0.05, 
**p < 0.01 and ***p < 0.001 were considered statistically 
significant. 
ACKNOWLEDGMENTS
This study was supported by the Basic Science 
Research Program and the International Research 
& Development Program through the National 
Research Foundation of Korea (NRF) funded by 
the Ministry of Science, ICT & Future Planning of 
Korea (NRF-2013R1A2A1A01009932 and NRF-
2014K1A3A7A03075054).
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
rEFErENcEs
1. Yuk JM and Jo EK. Host immune responses to 
mycobacterial antigens and their implications for the 
development of a vaccine to control tuberculosis. Clin Exp 
Vaccine Res. 2014; 3:155-167.
2. Reece ST and Kaufmann SH. Rational design of vaccines 
against tuberculosis directed by basic immunology. Int J 
Med Microbiol. 2008; 298:143-150.
Oncotarget24980www.impactjournals.com/oncotarget
3. Sable SB, Kalra M, Verma I and Khuller GK. Tuberculosis 
subunit vaccine design: the conflict of antigenicity and 
immunogenicity. Clin Immunol. 2007; 122:239-251.
4. Adekambi T, Ibegbu CC, Kalokhe AS, Yu T, Ray SM 
and Rengarajan J. Distinct effector memory CD4+ T cell 
signatures in latent Mycobacterium tuberculosis infection, 
BCG vaccination and clinically resolved tuberculosis. PLoS 
One. 2012; 7:e36046.
5. Steinman RM and Hemmi H. Dendritic cells: translating 
innate to adaptive immunity. Curr Top Microbiol Immunol. 
2006; 311:17-58.
6. Byun EH, Kim WS, Kim JS, Jung ID, Park YM, Kim HJ, 
Cho SN and Shin SJ. Mycobacterium tuberculosis Rv0577, 
a novel TLR2 agonist, induces maturation of dendritic cells 
and drives Th1 immune response. FASEB J. 2012; 26:2695-
2711.
7. Byun EH, Kim WS, Shin AR, Kim JS, Whang J, Won CJ, 
Choi Y, Kim SY, Koh WJ, Kim HJ and Shin SJ. Rv0315, 
a novel immunostimulatory antigen of Mycobacterium 
tuberculosis, activates dendritic cells and drives Th1 
immune responses. J Mol Med (Berl). 2012; 90:285-298.
8. Kim JS, Kim WS, Choi HG, Jang B, Lee K, Park JH, Kim 
HJ, Cho SN and Shin SJ. Mycobacterium tuberculosis RpfB 
drives Th1-type T cell immunity via a TLR4-dependent 
activation of dendritic cells. J Leukoc Biol. 2013; 94:733-
749.
9. Choi HG, Kim WS, Back YW, Kim H, Kwon KW, Kim 
JS, Shin SJ and Kim HJ. Mycobacterium tuberculosis 
RpfE promotes simultaneous Th1- and Th17-type T-cell 
immunity via TLR4-dependent maturation of dendritic 
cells. Eur J Immunol. 2015; 45:1957-1971.
10. Benini S and Wilson K. Structure of the Mycobacterium 
tuberculosis soluble inorganic pyrophosphatase Rv3628 at 
pH 7.0. Acta Crystallogr Sect F Struct Biol Cryst Commun. 
2011; 67:866-870.
11. Tammenkoski M, Benini S, Magretova NN, Baykov 
AA and Lahti R. An unusual, His-dependent family I 
pyrophosphatase from Mycobacterium tuberculosis. J Biol 
Chem. 2005; 280:41819-41826.
12. Rodina EV, Vainonen LP, Vorobyeva NN, Kurilova SA, 
Sitnik TS and Nazarova TI. Metal cofactors play a dual role 
in Mycobacterium tuberculosis inorganic pyrophosphatase. 
Biochemistry (Mosc). 2008; 73:897-905.
13. Gu S, Chen J, Dobos KM, Bradbury EM, Belisle JT 
and Chen X. Comprehensive proteomic profiling of the 
membrane constituents of a Mycobacterium tuberculosis 
strain. Mol Cell Proteomics. 2003; 2:1284-1296.
14. Mattow J, Schaible UE, Schmidt F, Hagens K, Siejak 
F, Brestrich G, Haeselbarth G, Muller EC, Jungblut PR 
and Kaufmann SH. Comparative proteome analysis of 
culture supernatant proteins from virulent Mycobacterium 
tuberculosis H37Rv and attenuated M. bovis BCG 
Copenhagen. Electrophoresis. 2003; 24:3405-3420.
15. Malen H, Pathak S, Softeland T, de Souza GA and Wiker 
HG. Definition of novel cell envelope associated proteins 
in Triton X-114 extracts of Mycobacterium tuberculosis 
H37Rv. BMC Microbiol. 2010; 10:132.
16. de Souza GA, Arntzen MO, Fortuin S, Schurch AC, Malen 
H, McEvoy CR, van Soolingen D, Thiede B, Warren RM 
and Wiker HG. Proteogenomic analysis of polymorphisms 
and gene annotation divergences in prokaryotes using a 
clustered mass spectrometry-friendly database. Mol Cell 
Proteomics. 2011; 10:M110 002527.
17. Sassetti CM and Rubin EJ. Genetic requirements for 
mycobacterial survival during infection. Proc Natl Acad 
Sci U S A. 2003; 100:12989-12994.
18. Triccas JA and Gicquel B. Analysis of stress- and host 
cell-induced expression of the Mycobacterium tuberculosis 
inorganic pyrophosphatase. BMC Microbiol. 2001; 1:3.
19. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, 
Akerley BJ and Sassetti CM. High-resolution phenotypic 
profiling defines genes essential for mycobacterial 
growth and cholesterol catabolism. PLoS Pathog. 2011; 
7:e1002251.
20. Rachman H, Strong M, Schaible U, Schuchhardt J, 
Hagens K, Mollenkopf H, Eisenberg D and Kaufmann 
SH. Mycobacterium tuberculosis gene expression profiling 
within the context of protein networks. Microbes Infect. 
2006; 8:747-757.
21. Jeon BY, Derrick SC, Lim J, Kolibab K, Dheenadhayalan 
V, Yang AL, Kreiswirth B and Morris SL. Mycobacterium 
bovis BCG immunization induces protective immunity 
against nine different Mycobacterium tuberculosis strains 
in mice. Infect Immun. 2008; 76:5173-5180.
22. Jeon BY, Kwak J, Hahn MY, Eum SY, Yang J, Kim SC 
and Cho SN. In vivo characteristics of Korean Beijing 
Mycobacterium tuberculosis strain K1 in an aerosol 
challenge model and in the Cornell latent tuberculosis 
model. J Med Microbiol. 2012; 61:1373-1379.
23. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG 
and Van Crevel R. Innate immune recognition of 
Mycobacterium tuberculosis. Clin Dev Immunol. 2011; 
2011:405310.
24. Takeda K and Akira S. Toll-like receptors in innate 
immunity. Int Immunol. 2005; 17:1-14.
25. Alto NM and Orth K. Subversion of cell signaling 
by pathogens. Cold Spring Harb Perspect Biol. 2012; 
4:a006114.
26. Diebold SS. Determination of T-cell fate by dendritic cells. 
Immunol Cell Biol. 2008; 86:389-397.
27. Ulrichs T, Anding P, Porcelli S, Kaufmann SH and Munk 
ME. Increased numbers of ESAT-6- and purified protein 
derivative-specific gamma interferon-producing cells in 
subclinical and active tuberculosis infection. Infect Immun. 
2000; 68:6073-6076.
Oncotarget24981www.impactjournals.com/oncotarget
28. Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder 
JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, 
Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA 
and Pantaleo G. Dominant TNF-alpha+ Mycobacterium 
tuberculosis-specific CD4+ T cell responses discriminate 
between latent infection and active disease. Nat Med. 2011; 
17:372-376.
29. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg 
E, Stone L, O’Rie T, Pienaar B, de Kock M, Kaplan G, 
Mahomed H, Dheda K and Hanekom WA. Functional 
capacity of Mycobacterium tuberculosis-specific T cell 
responses in humans is associated with mycobacterial load. 
J Immunol. 2011; 187:2222-2232.
30. Verwaerde C, Debrie AS, Dombu C, Legrand D, Raze D, 
Lecher S, Betbeder D and Locht C. HBHA vaccination may 
require both Th1 and Th17 immune responses to protect 
mice against tuberculosis. Vaccine. 2014; 32:6240-6250.
31. Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, 
Van Kaer L, Chattopadhyay D and Das G. Early Secreted 
Antigen ESAT-6 of Mycobacterium tuberculosis Promotes 
Protective T Helper 17 Cell Responses in a Toll-Like 
Receptor-2-dependent Manner. Plos Pathogens. 2011; 7.
32. Wang BL, Henao-Tamayo M, Harton M, Ordway D, 
Shanley C, Basaraba RJ and Orme IM. A toll-like receptor-
2-directed fusion protein vaccine against tuberculosis. Clin 
Vaccine Immunol. 2007; 14:902-906.
33. Richardson ET, Shukla S, Sweet DR, Wearsch PA, 
Tsichlis PN, Boom WH and Harding CV. Toll-Like 
Receptor 2-Dependent Extracellular Signal-Regulated 
Kinase Signaling in Mycobacterium tuberculosis- Infected 
Macrophages Drives Anti-Inflammatory Responses and 
Inhibits Th1 Polarization of Responding T Cells. Infection 
and Immunity. 2015; 83:2242-2254.
34. Harding CV and Boom WH. Regulation of antigen 
presentation by Mycobacterium tuberculosis: a role for 
Toll-like receptors. Nat Rev Microbiol. 2010; 8:296-307.
35. Bansal K, Sinha AY, Ghorpade DS, Togarsimalemath SK, 
Patil SA, Kaveri SV, Balaji KN and Bayry J. Src Homology 
3-interacting Domain of Rv1917c of Mycobacterium 
tuberculosis Induces Selective Maturation of Human 
Dendritic Cells by Regulating PI3K-MAPK-NF-kappa B 
Signaling and Drives Th2 Immune Responses. Journal of 
Biological Chemistry. 2010; 285:36511-36522.
36. Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak 
N, Siddiqui I, Sharma P, Hasnain SE, Mande SC and 
Mukhopadhyay S. The PPE18 of Mycobacterium 
tuberculosis Interacts with TLR2 and Activates IL-10 
Induction in Macrophage. Journal of Immunology. 2009; 
183:6269-6281.
37. Gehring AJ, Dobos KM, Belisle OT, Harding CV and 
Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): 
A novel TLR-2 ligand that inhibits human macrophage 
class II MHC antigen processing. Journal of Immunology. 
2004; 173:2660-2668.
38. Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler 
R, Bement T, Campos-Neto A, Skeiky YAW, Orme IM, 
Roberts A, Steen S, Dalemans W, Badaro R and Reed SG. 
Molecular characterization and human T-cell responses to a 
member of a novel Mycobacterium tuberculosis mtb39 gene 
family. Infection and Immunity. 1999; 67:2941-2950.
39. Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock 
M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, 
Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, 
Demoitie MA, Mettens P, Moris P, et al. Induction and 
Regulation of T-Cell Immunity by the Novel Tuberculosis 
Vaccine M72/AS01 in South African Adults. Am J Resp 
Crit Care. 2013; 188:492-502.
40. Liu SQ, Jia H, Hou SH, Zhang GM, Xin T, Li HG, 
Yuan WF, Guo XY, Gao XT, Li M, Wu J and Zhu HF. 
Recombinant TB10.4 of Mycobacterium bovis induces 
cytokine production in RAW264.7 macrophages through 
activation of the MAPK and NF-kappa B pathways via 
TLR2. Mol Immunol. 2014; 62:227-234.
41. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, 
Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler 
RN and Reed SG. Identification of human T cell antigens 
for the development of vaccines against Mycobacterium 
tuberculosis. J Immunol. 2008; 181:7948-7957.
42. Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, 
Hudson TE, Shaverdian N, O’Donnell J, Desbien AL, Reed 
SG and Coler RN. MyD88 and TRIF synergistic interaction 
is required for TH1-cell polarization with a synthetic TLR4 
agonist adjuvant. Eur J Immunol. 2013; 43:2398-2408.
43. Cluff CW. Monophosphoryl Lipid A (MPL) as an Adjuvant 
for Anti-Cancer Vaccines: Clinical Results. Adv Exp Med 
Biol. 2009; 667:111-123.
44. Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, 
Hudson TE, Shaverdian N, O’Donnell J, Desbien AL, Reed 
SG and Coler RN. MyD88 and TRIF synergistic interaction 
is required for TH1-cell polarization with a synthetic TLR4 
agonist adjuvant. European Journal of Immunology. 2013; 
43:2398-2408.
45. Baaten BJ, Tinoco R, Chen AT and Bradley LM. 
Regulation of Antigen-Experienced T Cells: Lessons from 
the Quintessential Memory Marker CD44. Front Immunol. 
2012; 3:23.
46. Baaten BJ, Li CR, Deiro MF, Lin MM, Linton PJ and 
Bradley LM. CD44 regulates survival and memory 
development in Th1 cells. Immunity. 2010; 32:104-115.
47. Day CL, Abrahams DA, Lerumo L, van Rensburg EJ, Stone 
L, O’rie T, Pienaar B, de Kock M, Kaplan G, Mahomed 
H, Dheda K and Hanekom WA. Functional Capacity of 
Mycobacterium tuberculosis-Specific T Cell Responses in 
Humans Is Associated with Mycobacterial Load. Journal of 
Immunology. 2011; 187:2222-2232.
48. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno 
J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, 
Locksley RM, Haynes L, Randall TD and Cooper AM. IL-
Oncotarget24982www.impactjournals.com/oncotarget
23 and IL-17 in the establishment of protective pulmonary 
CD4(+) T cell responses after vaccination and during 
Mycobacterium tuberculosis challenge. Nat Immunol. 2007; 
8:369-377.
49. Jeon BY, Kim SC, Eum SY and Cho SN. The immunity and 
protective effects of antigen 85A and heat-shock protein X 
against progressive tuberculosis. Microbes Infect. 2011; 
13:284-290.
